As leading consultants in the pharma and biotech industry, our experts are regularly discussing portfolio and asset management with investors and company stakeholders. We also sit on various public and private boards and regularly advise biotechs on their short- and long-term drug development strategies, helping to bring countless therapies to market.
Based on our experiences, we’ve gathered a wealth of lessons and best practices for what makes a program or asset successful.
In this article published in BioSpace, "When Should Biopharma Companies Buy, Partner or Develop Innovative Assets", our team discusses how to determine the right entry strategy for continued innovation.
Whether building a proprietary platform, acquiring another company or asset, or partnering with an established entity, it is important to consider resource allocation, risk management, and long-term viability.
Click here to read the full article published in BioSpace.
